ArticleBlood advances2026

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.